Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...

John Kempen, MD, MPH, PhD, MHS, Director of Epidemiology for Ophthalmology at Mass Eye and Ear and Harvard Medical School, is ...

Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...

John Kempen, MD, MPH, PhD, MHS , Director of Epidemiology for Ophthalmology at Mass Eye and Ear and Harvard Medical School, is the lead author of a ...

While online coaching improves asthma management short-term, it does not sustain physical activity changes, highlighting the ...

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of ...

New peer-reviewed research adds to substantial body of scientific evidence highlighting the safety of natural kratom leaf ...

Phase 2 trial of adults with Osteogenesis Imperfecta (OI) is enrolling patients in the US and EUWESTLAKE VILLAGE, Calif., ...

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in ...

The Centers for Disease Control and Prevention dropped its advice that kids get an annual flu shot at a time when flu cases ...

Trachoma is the leading cause of infectious blindness in the world, with Ethiopia the most impacted country in Africa. In a ...

SCOUT-HCM demonstrated the superiority of Camzyos on the primary endpoint and multiple secondary endpointsThe overall safety results in this study were consistent with the established safety profile ...